Strong NMD inhibition and low toxicity are two essential criteria for the identification and development of molecules liable to be used therapeutically, and NMD inhibitors are indeed viewed as potential candidates in the development of treatments for genetic diseases caused by a nonsense mutation. The gene discussed is PLA1A; the disease is hereditary disease.